It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

Casgevy is a gene-editing therapy which could be a game changer for CRISPR's business. The one-time treatment for sickle cell ...

The severity of these rarer types of sickle cell disease varies. — Hemoglobin S–beta-thalassemia: When individuals are diagnosed with this form of sickle cell disease, they inherit one sickle cell ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

He also believes there’s still too few of the therapies on the market to draw any sweeping conclusions on reasons for their ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

In addition, Vertex has partnered with CRISPR Therapeutics (CRSP) and received approval for Casgevy, a cell therapy treatment ...

Given all these factors, it seems reasonable to assume that Casgevy could grab at least a decent share, perhaps 20% of its ...

Developed in collaboration with Vertex Pharmaceuticals, this therapy treats sickle cell disease and transfusion-dependent ...

This growth stock reached dizzying heights during the pandemic, but came down to earth with a bump. Is it a bargain or ...